Newstral
Ingrezza
- A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund StarForbes
- MNeurocrine stock rockets to a record on sales beat—but can it last?marketwatch.com
- MNeurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expectedmarketwatch.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.